Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic zucker rats: Influence of the disease on the selectivity of action

Journal of Pharmacology and Experimental Therapeutics

Volumn 287, Issue 1, 1998, Pages 21-30

  Van Schaick, E A ^a   Zuideveld, K P ^a   Tukker, H E ^a   Langemeijer, M W E ^a   Ijzerman, A P ^a   Danhof, M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 N (4 SULFOPHENYL)ADENOSINE; ADENOSINE A1 RECEPTOR AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFECT; DRUG SELECTIVITY; GLUCOSE METABOLISM; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; LIPID METABOLISM; LIPOLYSIS; MALE; NONHUMAN; OBESITY; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT;

ADENOSINE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; HEMODYNAMIC PROCESSES; INSULIN; LIPOLYSIS; MALE; OBESITY; RATS; RATS, ZUCKER; RECEPTORS, PURINERGIC P1;

EID: 0032455713     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bogardus C, Lillioja S, Mott D, Hollenbeck C and Reaven G (1985) Relationship between degree obesity and in vivo insulin action in man. Am J Physiol 248:E286-291.
2. Bray GA (1977) The Zucker-fatty rat: A review. Fed Proc 36:148-153.
3. Cañas X, Fernández-López JA, Ardévol A, Adán C, Esteve M, Refecas I, Remesar X and Alemany M (1995) Rat insulin turnover in vivo Endocrinology 136:3871-3876.
4. 1 receptor agonists in streptozotocin-treated rats. J Cardiovasc Pharmacol 29:417-426.
5. Danhof M (1989) Does variability in drug disposition explain (all) variability in drug effects, in Topic on Pharmaceutical Sciences, pp. 573-586, Elsevier, Amsterdam.
6. Ferrannini E, Barret EJ and Bevilacqua S (1983) Effect of fatty acids on glucose production and utilization in man. J Clin Invest 72:1737-1747.
7. Foley JE (1992) Rationale and application of fatty acid oxidation inhibitors in the treatment of diabetes mellitus. Diabetes Care 15:773-784.
8. Frayn KN, Williams CM and Arner P (1996) Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases? Clin Sci 90:243-253.
9. Goetsch VL, VanDorsten B, Pbert LA, Ullrich IH and Yeater RA (1993) Acute effects of laboratory stress on blood glucose in non insulin-dependent diabetes. Psychosomatic Med 55:492-496.
10. 1 adenosine receptor agonist. J Biol Chem 262:15702-15707.
11. Gurden MF, Coates J, Ellis F, Evans B, Foster M, Hornby E, Kennedy I., Martin DP, Strong P, Vardey CJ and Wheeldon, A (1993) Functional characterisation of three adenosine receptors. Br J Pharmacol 109:693-698.
12. Hoffman BB, Dall'Aglio E, Hollenbeck C, Chang H and Reaven GM (1986) Suppression of fatty acids and triglycerides in normal and hypertriglyceridemic rats by the adenosine receptor agonist phenylisopropyladenosine. J Pharmacol Exp Ther 239: 715-718
13. IJzerman AP, Van der Wenden EM, Von Frijtag Drabbe Künzel JK, Mathôt RAA, Danhof M, Borea PA and Varani K (1994) Partial agonism of theophylline-7-riboside on adenosine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 350: 638-645.
14. Jaber LA, Ducharme MP and Halapy (1996) The effects of obesity on the pharmacokinetics and pharmacodynamics of Glipizide in patients with non-insulin dependent diabetes mellitus. Ther Drug Monitor 18:6-13.
15. Jacobson KA, Trivedi BK, Churchill PC and Williams M (1991) Novel therapeutics acting via purine receptors. Biochem Pharmacol 41:1399-1410.
16. 6-sulfoalkyl derivatives of adenosine: Water-soluble and peripherally selective adenosine agonists. J Med Chem 35:4143-4149.
17. Jusko WJ and Ko HC (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56:406-419.
18. Jusko WJ and Chiang ST (1982) Distribution volume related to body weight and protein binding. J Pharm Sci 71:469-470.
19. Kaartinen JM, LaNoue KF and Ohisalo JJ (1994) Quantification of inhibitory G-proteins in fat cells of obese and normal-weight human subjects. Biochim Biophys Acta 1201:69-75.
20. Karasik A and Hattori M (1994) Use of animal models in the study of diabetes, in: Joslin's diabetes mellitus pp. 193-200, Lea&Febiger, Philidelpia.
21. Kurtz TW, Morris RC and Pershadsingh HA (1989) The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 13:896-901
22. 1 adenosine receptor function in genetic obesity. FASEB 8:72-80.
23. LeBlanc J and Soucy J (1994) Hormonal dose-response to an adenosine receptor agonist. Can J Physiol Pharmacol 72:113-116.
24. Levy G (1985) Variability in animal and human pharmacodynamic studies, in Variability in Drug Therapy: Description, Estimation and Control pp. 125-138. Raven Press, New York.
25. 6-cyclopentyladenosine in the rat. J Pharmacol Exp Ther 268:616-624.
26. 1 receptor in vivo Br J Pharmacol 116:1957-1964.
27. McCaleb ML and Sredy J (1992) Metabolic abnormalities of the hyperglycemic obese Zucker rat. Metabolism 41:522-525.
28. Ohisalo JJ, Ranta S and Huhtaniemi LT (1986) Attenuated adenosine R-site effect in adipocytes in obesity. Metabolism 35:143-146.
29. Reaven GM and Chen Y-D.I (1988) Role of abnormal free fatty acid metabolism in the development of non-insulin dependent diabetes mellitus. Am J Med 85:106-112
30. Reaven GM, Chang H, Ho H, Jeng CI and Hoffman BB (1988) Lowering of plasma glucose in diabetic rats by antilipolytic agents. Am J Physiol 254:E23-30.
31. Rohner-Jeanrenaud, F., Proietto, J., Ionescu, E. and Jeanrenaud, B.: Mechanism of abmormal oral glucose tolerance of genetically obese fa/fa rats. Diabetes 35:1350-1355, (1986)
32. Shum L and Jusko WJ (1984) Theophylline disposition in obese rats. J Pharmacol Exp Ther 228:360-366.
33. Strong P, Anderson R, Coates J, Ellis F, Evans B, Gurden MF, Johnstone J, Kennedy I and Martin DP (1993) Suppression of non esterified fatty acids and triacylglycerol in experimental animals by the adenosine analogue GR79236. Clin Sci 84: 663-669.
34. Terrattaz J, Assimacopoulos-Jeannet F and Jeanrenaud B (1986) Severe hepatic and peripheral insulin resistance as evidenced by euglymic clamps in genetically obese fa/fa rats. Endocrinology 188:674-678.
35. 6-(p-sulfophenyl)adenosine in rats. Br J Pharmacol 122:525-533.
36. 1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects. Naunyn Schmiedeberg's Archives of Pharmacology 356:827-837.
37. 1 receptor agonists. J Pharmacokin Biopharm (in press).
38. 1 mediated inhibition. Int J Obesity 14:125-134.
39. Vannucci SJ, Klim CM, Martin LF and Lanoue KF (1989) Aradenosine receptor-mediated inhibition of adipocyte adenylate cyclase and lipolysis in Zucker rats. Am J Physiol 257:E871-E878
40. Zemel MB, Peuler JD, Sowers JR and Simpson L (1992) Hypertension in insulin-resistant Zucker obese rats is independent of sympathetic neural support. Am J Physiol 262:E368-E373
41. Zucker LM and Zucker TF (1961) Fatty, a new mutation in the rat. J Hered 52:275-278.